Prospective evaluation of the effects of antiretroviral therapy on body composition in HIV-1-infected men starting therapy.
about
Low dose versus high dose stavudine for treating people with HIV infectionThe role of protease inhibitors in the pathogenesis of HIV-associated lipodystrophy: cellular mechanisms and clinical implicationsMetabolic syndrome, diabetes, and cardiovascular risk in HIVHIV/AIDS and lipodystrophy: implications for clinical management in resource-limited settingsIncreasing rates of obesity among HIV-infected persons during the HIV epidemicDifferential adipose tissue gene expression profiles in abacavir treated patients that may contribute to the understanding of cardiovascular risk: a microarray studyComparing the Ability of Anthropometric Indicators in Identifying Metabolic Syndrome in HIV PatientsLipodystrophy and weight changes: data from the Swiss HIV Cohort Study, 2000-2006.Dietary intake and body composition in HIV-positive and -negative South African womenDyslipidemia and adherence to the Mediterranean diet in Croatian HIV-infected patients during the first year of highly active antiretroviral therapy.Assessment of ultrasound for use in detecting lipoatrophy in HIV-infected patients taking combination antiretroviral therapy.Low bone-mineral density in patients with HIV: pathogenesis and clinical significance.HIV-associated lipodystrophy: a review from a Brazilian perspectiveHIV infection.Indices of body fat distribution for assessment of lipodysthrophy in people living with HIV/AIDS.Reducing plasma HIV RNA improves muscle amino acid metabolism.Body fat redistribution and metabolic abnormalities in HIV-infected patients on highly active antiretroviral therapy: novel insights into pathophysiology and emerging opportunities for treatment.Early loss of bone mineral density is correlated with a gain of fat mass in patients starting a protease inhibitor containing regimen: the prospective Lipotrip study.Changes in Body Mass Index Following HAART Initiation among HIV-Infected Women in the Women's Interagency HIV Study.HIV lipodystrophy in participants randomised to lopinavir/ritonavir (LPV/r) +2-3 nucleoside/nucleotide reverse transcriptase inhibitors (N(t)RTI) or LPV/r + raltegravir as second-line antiretroviral therapy.Antiretroviral therapies associated with lipoatrophy in HIV-infected womenRegional anthropometry changes in antiretroviral-naïve persons initiating a Zidovudine-containing regimen in Mbarara, Uganda.Peripheral and central fat changes in subjects randomized to abacavir-lamivudine or tenofovir-emtricitabine with atazanavir-ritonavir or efavirenz: ACTG Study A5224s.Metabolic syndrome in HIV-infected patients from an urban, midwestern US outpatient population.Longitudinal anthropometric patterns among HIV-infected and HIV-uninfected women.Genetic analysis implicates resistin in HIV lipodystrophy.New and emerging agents in the management of lipodystrophy in HIV-infected patients.Chronic noncommunicable diseases and HIV-AIDS on a collision course: relevance for health care delivery, particularly in low-resource settings--insights from South AfricaBone disease in HIV infection.Switching to a protease inhibitor-containing, nucleoside-sparing regimen (lopinavir/ritonavir plus efavirenz) increases limb fat but raises serum lipid levels: results of a prospective randomized trial (AIDS clinical trial group 5125s).Update on HIV lipodystrophy.Lipodystrophy in Human Immunodeficiency Virus (HIV) Patients on Highly Active Antiretroviral Therapy (HAART).Adverse effects of antiretroviral therapy for HIV infection: a review of selected topics.Care of the human immunodeficiency virus-infected menopausal woman.Safety of lopinavir/ritonavir for the treatment of HIV-infection.People living with HIV on ART have accurate perception of lipodystrophy signs: a cross-sectional study.Toxic metabolic syndrome associated with HAART.HIV-1 infection and antiretroviral therapies: risk factors for osteoporosis and bone fracture.Approach to the human immunodeficiency virus-infected patient with lipodystrophyAntiretroviral treatment of HIV infection: Swedish recommendations 2007.
P2860
Q24242088-3F86942F-19E6-4814-A2D3-E8F6565AF218Q24598812-C3014EEB-5040-4477-8E9C-189153D39D1FQ26853470-AC016A9C-1B12-4B95-B982-5925F84371C1Q28088839-93F7D225-CA09-4940-A5EF-322886551197Q28473706-0EFDCB6F-3A2C-47E9-B8E7-A18CB0EAEBC9Q28543075-54341813-D069-42F8-A66C-6C55F509B317Q28550389-E543C8B2-DC4C-4B4A-B459-85774285C07AQ31143771-F193B8DE-150D-4CAE-9FAF-245EC849C357Q33711577-EA58B17B-7935-4E8A-B167-EC02E825508FQ33747646-3EF90112-CD45-4D3C-BFE5-8A3C666E0674Q33797575-7AE30F42-6DAF-4BF5-9981-3F4400A2AB12Q33844059-6E6A72F5-85A4-4419-BF7D-9449C6A2416BQ33939681-7FA53D46-EE32-4CA3-B865-8DBEB44C6938Q34011172-8E2A86A8-6761-4B5C-92FF-AEE7191A37E5Q34432001-1DB3C5C5-2F04-486F-86C4-533E50D2159FQ34550863-13F49367-4CF7-40FB-A0CF-3DDB026CC050Q34564973-812A7B8D-0844-4A0A-9C0E-C75D901B15BFQ34786514-CB87AE38-63B1-4F1F-9686-FC439CA2E3D8Q34849237-0384D2F7-5852-4A93-913C-04F7BC42F544Q35035055-08AE9E47-1FAB-4E4F-B385-11D81FA08E30Q35097650-596B4AB3-18E2-4E3E-9980-B9707F6F73ADQ35173638-9994B8FA-55E2-462F-B2CA-BDB6799711FEQ35193326-33B728B1-8F16-4014-A49C-1FD683C74EDBQ35206670-4113B0A0-B325-4A2D-9407-1A131652BB33Q35525087-F6570593-D4F6-4014-B4FD-8DE989283E45Q35538933-FE2F1B6E-B3D5-4DCB-94B4-F160559EA8CDQ35557229-F5F09D31-6858-4B50-9DF7-CFC74F3525F4Q35578696-5BF46018-4334-4933-8F2E-25DD1A25DD6EQ35593296-9037DFDC-83C0-40A4-9A0D-CE529753F962Q35637346-6C6493D1-AE28-4AD8-80BD-F6D063223D06Q35833512-F9B66950-4B8C-4455-9662-E4C8C4F0FD31Q36068146-43848804-FD0D-46B0-B932-B4B75121B44FQ36081993-454C2C12-502F-4116-997B-5E917F63F047Q36128333-E241C344-9AA7-4651-B709-B078F1F67EDFQ36150530-51DAAA52-DA11-431E-9DD8-F44C3B0308BCQ36249550-065CA102-7799-463A-A949-BDC0090D8273Q36544924-5F0042E9-C29D-4722-BE5A-34A64DACD629Q36783435-62E4E0BA-7984-4612-87B6-A295DD1E8762Q36834945-2914302D-3327-4FDA-8463-D0AA217538C7Q36852859-2D13D9E4-EF37-419E-A14A-C43B68EC4097
P2860
Prospective evaluation of the effects of antiretroviral therapy on body composition in HIV-1-infected men starting therapy.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年学术文章
@wuu
2003年学术文章
@zh
2003年学术文章
@zh-cn
2003年学术文章
@zh-hans
2003年学术文章
@zh-my
2003年学术文章
@zh-sg
2003年學術文章
@yue
2003年學術文章
@zh-hant
name
Prospective evaluation of the ...... infected men starting therapy.
@en
Prospective evaluation of the ...... infected men starting therapy.
@nl
type
label
Prospective evaluation of the ...... infected men starting therapy.
@en
Prospective evaluation of the ...... infected men starting therapy.
@nl
prefLabel
Prospective evaluation of the ...... infected men starting therapy.
@en
Prospective evaluation of the ...... infected men starting therapy.
@nl
P2093
P1433
P1476
Prospective evaluation of the ...... infected men starting therapy.
@en
P2093
Andrew Carr
David A Cooper
John Miller
Patrick W Mallon
P304
P356
10.1097/00002030-200305020-00005
P407
P577
2003-05-01T00:00:00Z